Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

ER-Positive Metastatic Breast Cancer — An Interview with Prof Patrick Neven on the Role of Oral Selective Estrogen Receptor Degraders

41:17
 
Share
 

Manage episode 517910781 series 2530615
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Featuring an interview with Prof Patrick Neven, including the following topics:

  • Emergence of ESR1 mutations in ER-positive, HER2-negative breast cancer (0:00)
  • Observed toxicity profile of oral selective estrogen receptor degraders (SERDs) (3:57)
  • Emerging data with novel oral SERD combinations (6:31)
  • Challenges for a general medical oncologist in breast cancer (8:41)
  • Sequencing and selection of therapies in ER-positive, HER2-negative breast cancer (12:16)
  • Evaluating the strategy of switching to an oral SERD during first-line endocrine therapy upon "molecular progression" (23:16)

CME information and select publications

  continue reading

782 episodes

Artwork
iconShare
 
Manage episode 517910781 series 2530615
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Featuring an interview with Prof Patrick Neven, including the following topics:

  • Emergence of ESR1 mutations in ER-positive, HER2-negative breast cancer (0:00)
  • Observed toxicity profile of oral selective estrogen receptor degraders (SERDs) (3:57)
  • Emerging data with novel oral SERD combinations (6:31)
  • Challenges for a general medical oncologist in breast cancer (8:41)
  • Sequencing and selection of therapies in ER-positive, HER2-negative breast cancer (12:16)
  • Evaluating the strategy of switching to an oral SERD during first-line endocrine therapy upon "molecular progression" (23:16)

CME information and select publications

  continue reading

782 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play